Our news editors obtained a quote from the research from Pfizer, "However, in a discovery bioanalytical ligand-binding assay laboratory setting where the focus is not necessarily on sample analysis throughput, but instead on assay development and characterization, is automation applicable? Can automation enhance productivity when tasks are more customized than routine? In this Perspective we review the different categories of automation with ligand-binding assays with these questions in mind. In considering whether automation technology has progressed far enough to result in a positive return in investment in the discovery setting, the resource investment required to operate in this space was contrasted with the gain in productivity."
According to the news editors, the research concluded: "In our opinion, technology advancements in automated technology platforms, and especially personal automation, have allowed these categories to strike the right balance for investment in the discovery laboratory setting."
For more information on this research see: Automate it: ligand-binding assay productivity in a discovery bioanalytical setting. Bioanalysis, 2013;5(14):1775-82.
The news editors report that additional information may be obtained by contacting S.S. Leung, Pharmacokinetics Dynamics & Metabolism,
Keywords for this news article include:
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC
Most Popular Stories
- U.S. Growth Stayed Steady During Shutdown, Fed Says
- Hezbollah Chief's Assassination Claimed by Sunni Group
- Newtown Massacre Heard on 911 Recordings
- Allstate Seeks to Invest in Minority Firms
- Reid Confident Congress to Pass Immigration Bill
- Latin Music Conference Turns 25
- Guardian Pressured to Stop NSA Stories: Editor
- New Home Sales Shoot up 25 Percent in October
- Boehner Blames Obama, Senate for Congressional Inactivity
- Liberty Power Gets Minority Business Nod